Remove 2030 Remove Insurance Remove Packaging
article thumbnail

Chugai and Gero link on antibody drugs for age-related conditions

Pharmaceutical Technology

Chugai president and CEO Dr Osamu Okuda stated: “We believe that open innovation with external partners, including leading global players, is extremely important for achieving global first-class drug discovery outlined in our growth strategy toward 2030, TOP I 2030. “By How will RFK Jr’s American dream for vaccines play out?

article thumbnail

GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients

Pharmaceutical Technology

The global RSV market is set to reach $6.3bn in value by 2030, according to analysis by GlobalData. How will RFK Jr’s American dream for vaccines play out? Sectors Sections Clinical Trials Drug Manufacturers Therapy Area Pricing and Market Access Latest EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma Formulate Faster.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

UK steps up with £1.25bn Gavi vaccine pledge as US funding disappears

Pharmaceutical Technology

The group had set a fundraising target of $11.9bn for its 2026-2030 budget. Robert Barrie June 26, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Gavi conducted a fundraiser at its annual Global Summit held in Brussels on 25 June. The organisation raised more than $9bn, less than it had targeted.

article thumbnail

FDA approves label expansion of AbbVie hepatitis C therapy

Pharmaceutical Technology

. “The label expansion for Mavyret, coupled with the implementation of ‘test and treat’ models of care, serves as a tool to support the public health community in treating more patients and bringing us closer to achieving the global 2030 elimination goal.” Give your business an edge with our leading industry insights.

article thumbnail

Philips on designing innovation and cultivating partnerships – part two

pharmaphorum

In the cities, there are a lot of private providers, and those who can afford it or those who have insurance have access to quality care. It’s a package, and sometimes we deploy one or two modules, sometimes multiple modules in a project. The only aspects Philips does not provide are health workers and the supply chain for drugs.

article thumbnail

AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancer

Pharmaceutical Technology

GlobalData’s Pharma Intelligence Center forecasts global sales for the drug to peak in 2030, generating $7bn in revenue. How will RFK Jr’s American dream for vaccines play out? With entry to the market, Imfinzi stands alone as the only perioperative immunotherapy for muscle-invasive bladder cancer.

article thumbnail

Big pharma braces for revenue headwinds as patent expiries loom

Pharmaceutical Technology

Robert Barrie July 4, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Only 4% of global drugs sales in 2030 will have patent protection. A recent report by GlobalData projects that the share of global drug sales under patent protection will decline by 2030. How will RFK Jr’s American dream for vaccines play out?